Insulin Sensitizing Drugs

Česká verzia

Authors: A. Šmahelová
Authors place of work: Diabetologické centrum, vedoucí doc. MUDr. Alena Šmahelová, Ph. D., Kliniky gerontologické a metabolické Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Luboš Sobotka, CSc.
Published in the journal: Vnitř Lék 2009; 55(4): 425-428
Category:

Summary

Currently, insulin sensitizing drugs in the form of metformin as the basic drug are part of the treatment of practically any type II diabetic patient. At the beginning of the therapy, metformin is used; later, insulin sensitizers (PPAR‑γ stimulators) such as rosiglitazone and pioglitazone are often applied. Nowadays, extensive research into new pharmaceuticals is being conducted in the group of insulin sensitizers. So-called double sensitizers, panPPAR sensitizers or PPAR‑γ sensitizers, are being developed. The most promising group is of the PPAR‑γ selective modulators.

Key words:
metformin – rosiglitazone – pioglitazone – PPAR sensitizers – selective PPAR modulators – panPPAR sensitizers

Zdroje

1. Zwieten PA, Lancia G. The metabolic syndrome – a therapeutic chalenge. European society of hypertension 2005.

2. Nathan DM, Buse JB, Davidson MB et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.

3. Rosenstock J. Reflecting on type 2 diabetes prevention: more questions than answers. Diabetes Obes Metab 2007; 9 (Suppl 1): 3–11.

4. Šmahelová A. Metformin. In: Haluzík M (ed). Trendy v endokrinologii č. 12. Praha: Galén 2008.

5. DPP Research group: The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25: 2165–2171.

6. Haluzík M, Svačina Š. Metabolický syndrom a jaderné receptory PPAR. Praha: Grada Publishing 2005.

7. Cavaghan MK, Ehrmann DA, Byrne MM et al. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100: 530–537.

8. Kahn SE, Haffner SM, Heise MA et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–2443.

9. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118.

10. Goldberg RB, Kendall DM, Deeg MA et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547–1554.

11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471.

12. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–1289.

13. Home PD, Jones NP, Pocock SJ et al. RECORD Study Group. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007; 24: 626–634.

14. Loke YK, Singh S, Furberg CD. Long‑term use of thiazolidinediones and fractures in type 2 diabetes: a meta‑analysis. CMAJ 2009; 180: 32–39.

15. Svačina Š. Prevence diabetu a jeho komplikací. Praha: Triton 2008.

16. Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007; 21: 687–710.

17. Svačina Š. Metabolické receptory PPAR a kůže. Vnitř Lék 2006; 52: 451–453.

18. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator‑activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005; 4: 14.